Company profile
DBV Technologies S.A.
NASDAQ:DBVTBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03352726 | phase1 | completed | 2017-11-24 | 2018-06-29 | DBV Technologies | A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects |
| NCT01675882 | phase2 | completed | 2012-08-01 | 2014-07-01 | DBV Technologies | Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy |
| NCT02223182 | phase1_2 | completed | 2014-11-01 | 2017-12-14 | DBV Technologies | Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy |
| NCT02636699 | phase3 | completed | 2015-12-01 | 2017-08-18 | DBV Technologies | Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy |
| NCT03859700 | phase3 | completed | 2018-12-06 | 2025-05-13 | DBV Technologies | Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children |
FDA applications (0)
No records yet.